The regional association between bronchiectasis and lung cancer in chest CT

Kim, Yeon Wook; Lee, Chang Hoon; Jin, Kwang Nam; Lee, Jung Kyu; Heo, Eun Young; Chung, Hee Soon; Kim, Deog Kyeom

doi:10.1186/s12890-016-0311-4

Cited by 6 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, ionizing radiation, gene and other lung diseases such as pulmonary tuberculosis and bronchiectasis increase the risk of NSCLC. [ 16 – 18 ] This study shows that family history and smoking history of NSCLC can increase the incidence of NSCLC, which is consistent with many studies. [ 19 ] And the serum lipids TC, TG, LDL, RBP4 in NSCLC patients are higher than those in normal people, and HDL is lower than that of normal people.…”

Section: Discussionsupporting

confidence: 90%

Serum levels of retinol-binding protein 4 and the risk of non-small cell lung cancer

Hu¹,

Huang²,

Wang³

et al. 2020

Medicine

View full text Add to dashboard Cite

Retinol binding protein 4 (RBP4), as an adipokine, has been identified to be associated with several types of cancer. However, no studies have assessed its effect on non-small cell lung cancer (NSCLC) risk. The objective of this study was to assess the association between serum RBP4 levels and the risk of NSCLC. A case-control study design was used to recruit 256 confirmed NSCLC cases and 256 age- and gender-matched healthy controls by frequency between August 2017 and January 2019. Serum RBP4 was measured using enzyme-linked immune absorbent assay before treatment. Unconditional logistic regression analysis was applied to estimate the odds ratio and 95% confidence interval (CI). Serum RBP4 level was significantly higher in NSCLC patients than those in the healthy control group (36.05 ± 8.28 vs 29.54 ± 7.71 μg/mL, P < .05). Higher serum RBP4 level was associated with increased risk of NSCLC ( P trend = .001). Compare with those in the lowest tertile, the adjusted odds ratios were 1.85 (95% CIs 1.07–3.2) ( P = .029) for the second tertile and 2.18 (95% CIs 1.37–3.45) ( P = .001) for the highest tertile after adjusting for confounding variables. No interactions were observed after stratified analyses by body mass index and smoking status ( P for interaction: .584 and .357). Our study indicated that serum RBP4 level was positively related to the risk of NSCLC. Additional studies with prospective design are required to confirm this finding.

show abstract

Section: Discussionsupporting

confidence: 90%

Serum levels of retinol-binding protein 4 and the risk of non-small cell lung cancer

Hu¹,

Huang²,

Wang³

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

“…In fact, respiratory related deaths have been known to be a major cause of death in bronchiectasis [9, 19, 20]. In addition, to our knowledge, we reported here for the first time the higher risk of lung cancer-related mortality in those with bronchiectasis even after adjustment of smoking history, although there are several studies that have investigated the association of bronchiectasis with the incidence of lung cancer in Asian populations [21, 22]. Chronic inflammation and recurrent infections, which are generally accepted mechanisms for cancer development [23, 24], may contribute to the development of lung cancer in bronchiectasis patients; however, the exact biological mechanism needs further clarification.…”

Section: Discussionmentioning

confidence: 54%

Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis

et al. 2019

Self Cite

View full text Add to dashboard Cite

BackgroundAll-cause mortality risk and causes of death in bronchiectasis patients have not been fully investigated. The aim of this study was to compare the mortality risk and causes of death between individuals with bronchiectasis and those without bronchiectasis.MethodsPatients with or without bronchiectasis determined based on chest computed tomography (CT) at one centre between 2005 and 2016 were enrolled. Among the patients without bronchiectasis, a control group was selected after applying additional exclusion criteria. We compared the mortality risk and causes of death between the bronchiectasis and control groups without lung disease. Subgroup analyses were also performed according to identification of Pseudomonas or non-tuberculous mycobacteria, airflow limitation, and smoking status.ResultsOf the total 217,702 patients who underwent chest CT, 18,134 bronchiectasis patients and 90,313 non-bronchiectasis patients were included. The all-cause mortality rate in the bronchiectasis group was 1608.8 per 100,000 person-years (95% confidence interval (CI), 1531.5–1690.0), which was higher than that in the control group (133.5 per 100,000 person-years; 95% CI, 124.1–143.8; P < 0.001). The bronchiectasis group had higher all-cause (adjusted hazard ratio (aHR), 1.26; 95% CI, 1.09–1.47), respiratory (aHR, 3.49; 95% CI, 2.21–5.51), and lung cancer-related (aHR, 3.48; 95% CI, 2.33–5.22) mortality risks than the control group. In subgroup analysis, patients with airflow limitation and ever smokers showed higher all-cause mortality risk among bronchiectasis patients. Therefore, we observed significant interrelation between bronchiectasis and smoking, concerning the risks of all-cause mortality (P for multiplicative interaction, 0.030, RERI, 0.432; 95% CI, 0.097–0.769) and lung cancer-related mortality (RERI, 8.68; 95% CI, 1.631–15.736).ConclusionIndividuals with bronchiectasis had a higher risk of all-cause, respiratory, and lung cancer-related mortality compared to control group. The risk of all-cause mortality was more prominent in those with airflow limitation and in ever smokers.

show abstract

“…In fact, respiratory related deaths have been known to be a major cause of death in bronchiectasis [9,19,20]. In addition, to our knowledge, we reported here for the first time the higher risk of lung cancer-related mortality in those with bronchiectasis even after adjustment of smoking history, although there are several studies that have investigated the association of bronchiectasis with the incidence of lung cancer in Asian populations [21,22]. Chronic inflammation and recurrent infections, which are generally accepted mechanisms for cancer development [23,24], may contribute to the development of lung cancer in bronchiectasis patients; however, the exact biological mechanism needs further clarification.…”

Section: Discussionmentioning

confidence: 46%

Mortality Risk and Causes of Death in Patients with Non-Cystic Fibrosis Bronchiectasis

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background: All-cause mortality risk and causes of death in bronchiectasis patients have not been fully investigated. The aim of this study was to compare the mortality risk and causes of death between individuals with bronchiectasis and those without bronchiectasis. Methods: Patients with or without bronchiectasis determined based on chest computed tomography (CT) at one centre between 2005 and 2016 were enrolled. Among the patients without bronchiectasis, a control group was selected after applying additional exclusion criteria. We compared the mortality risk and causes of death between the bronchiectasis and control groups without lung disease. Subgroup analyses were also performed according to identification of Pseudomonas or non-tuberculous mycobacteria, airflow limitation, and smoking status. Results: Of the total 217,702 patients who underwent chest CT, 18,134 bronchiectasis patients and 90,313 nonbronchiectasis patients were included. The all-cause mortality rate in the bronchiectasis group was 1608.8 per 100,000 person-years (95% confidence interval (CI), 1531.5-1690.0), which was higher than that in the control group (133.5 per 100,000 person-years; 95% CI, 124.1-143.8; P < 0.001). The bronchiectasis group had higher all-cause (adjusted hazard ratio (aHR), 1.26; 95% CI, 1.09-1.47), respiratory (aHR, 3.49; 95% CI, 2.21-5.51), and lung cancer-related (aHR, 3.48; 95% CI, 2.33-5.22) mortality risks than the control group. In subgroup analysis, patients with airflow limitation and ever smokers showed higher all-cause mortality risk among bronchiectasis patients. Therefore, we observed significant interrelation between bronchiectasis and smoking, concerning the risks of all-cause mortality (P for multiplicative interaction, 0.030, RERI, 0.432; 95% CI, 0.097-0.769) and lung cancer-related mortality (RERI, 8.68; 95% CI, 1.631-15.736). Conclusion: Individuals with bronchiectasis had a higher risk of all-cause, respiratory, and lung cancer-related mortality compared to control group. The risk of all-cause mortality was more prominent in those with airflow limitation and in ever smokers.

show abstract

The regional association between bronchiectasis and lung cancer in chest CT

Cited by 6 publications

References 22 publications

Serum levels of retinol-binding protein 4 and the risk of non-small cell lung cancer

Serum levels of retinol-binding protein 4 and the risk of non-small cell lung cancer

Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis

Mortality Risk and Causes of Death in Patients with Non-Cystic Fibrosis Bronchiectasis

Contact Info

Product

Resources

About